KR20240021227A - 방사성면역접합체와 체크포인트 억제제의 조합 요법 - Google Patents

방사성면역접합체와 체크포인트 억제제의 조합 요법 Download PDF

Info

Publication number
KR20240021227A
KR20240021227A KR1020247000772A KR20247000772A KR20240021227A KR 20240021227 A KR20240021227 A KR 20240021227A KR 1020247000772 A KR1020247000772 A KR 1020247000772A KR 20247000772 A KR20247000772 A KR 20247000772A KR 20240021227 A KR20240021227 A KR 20240021227A
Authority
KR
South Korea
Prior art keywords
ser
antibody
alkyl
cancer
kbq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000772A
Other languages
English (en)
Korean (ko)
Inventor
에릭 스티븐 부락
줄리 메트칼프
나탈리 그린슈타인
메이두오 후
존 피츠모리스 밸리언트
Original Assignee
퓨전 파마슈티칼즈 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퓨전 파마슈티칼즈 인크. filed Critical 퓨전 파마슈티칼즈 인크.
Publication of KR20240021227A publication Critical patent/KR20240021227A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247000772A 2021-06-11 2022-06-10 방사성면역접합체와 체크포인트 억제제의 조합 요법 Pending KR20240021227A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209736P 2021-06-11 2021-06-11
US63/209,736 2021-06-11
PCT/US2022/033058 WO2022261467A1 (en) 2021-06-11 2022-06-10 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (1)

Publication Number Publication Date
KR20240021227A true KR20240021227A (ko) 2024-02-16

Family

ID=84426354

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000772A Pending KR20240021227A (ko) 2021-06-11 2022-06-10 방사성면역접합체와 체크포인트 억제제의 조합 요법

Country Status (13)

Country Link
US (1) US20240285818A1 (https=)
EP (1) EP4351662A1 (https=)
JP (1) JP2024521418A (https=)
KR (1) KR20240021227A (https=)
CN (1) CN117794585A (https=)
AR (1) AR126128A1 (https=)
AU (1) AU2022291150A1 (https=)
BR (1) BR112023026076A2 (https=)
CA (1) CA3222948A1 (https=)
IL (1) IL309243A (https=)
MX (1) MX2023014778A (https=)
TW (1) TW202317204A (https=)
WO (1) WO2022261467A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577527A1 (en) * 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Vhh antibody dota conjugates
KR20250171285A (ko) * 2023-04-12 2025-12-08 코넬 유니버시티 암 치료용 방사선치료 접합체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds

Also Published As

Publication number Publication date
EP4351662A1 (en) 2024-04-17
CN117794585A (zh) 2024-03-29
BR112023026076A2 (pt) 2024-03-05
WO2022261467A1 (en) 2022-12-15
IL309243A (en) 2024-02-01
CA3222948A1 (en) 2022-12-15
WO2022261467A9 (en) 2023-05-04
JP2024521418A (ja) 2024-05-31
AU2022291150A1 (en) 2023-12-21
US20240285818A1 (en) 2024-08-29
TW202317204A (zh) 2023-05-01
AR126128A1 (es) 2023-09-13
MX2023014778A (es) 2024-01-15

Similar Documents

Publication Publication Date Title
JP7191938B2 (ja) Ｉｇｆ－１ｒモノクローナル抗体及びその使用
KR20210099073A (ko) 방사성면역접합체와 체크포인트 억제제의 조합 요법
ES2861499T3 (es) Anticuerpos anti-B7-H3 y conjugados anticuerpo-fármaco
KR102612882B1 (ko) 이관능성 킬레이트 및 그의 용도의 약동학적 증진
KR20230038738A (ko) 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
KR20160037130A (ko) 신규한 항체 접합체 및 이의 용도
CN110997725A (zh) 抗-il1rap抗体和抗体药物缀合物
JP2018524295A (ja) 抗体及び免疫複合体
CN118922210A (zh) B7h4抗体药物偶联物及其用途
KR20240021227A (ko) 방사성면역접합체와 체크포인트 억제제의 조합 요법
WO2024212960A1 (zh) 抗Trop2抗体-自然杀伤细胞偶联物及其用途
HK40109328A (zh) 放射免疫缀合物及检查点抑制剂组合疗法
JP2023518818A (ja) Ｆｇｆｒ３に標的化されたラジオイムノコンジュゲートおよびその使用
HK40058366A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
HK40060346A (en) Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
HK40118862A (zh) 抗-il1rap抗体和抗体药物缀合物
WO2025185559A1 (zh) 抗FGFR2b抗体、其抗体药物偶联物及其用途
HK40027179B (zh) 抗-il1rap抗体和抗体药物缀合物
HK40027179A (en) Anti-il1rap antibodies and antibody drug conjugates

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240109

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250528

Comment text: Request for Examination of Application